Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Disc Medicine, Inc. - Common Stock (NQ:IRON)

69.43 -1.98 (-2.77%)
Streaming Delayed Price Updated: 11:20 AM EDT, Apr 21, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Disc Medicine, Inc. - Common Stock

< Previous 1 2 3 4 Next >
News headline image
Disc Medicine Announces Oral Presentation of Data from RALLY-MF Phase 2 Trial of DISC-0974 in Patients with Myelofibrosis and Anemia at the American Society of Clinical Oncology (ASCO) Annual Meeting
From Disc Medicine Inc
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Disc Medicine, Inc. - IRON
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Disc Medicine, Inc. - IRON
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Disc Medicine, Inc. - IRON
From Pomerantz LLP
Via GlobeNewswire
News headline image
IRON Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
Disc Medicine Announces Completion of Enrollment of Phase 3 APOLLO Trial of Bitopertin in Erythropoietic Protoporphyria
From Disc Medicine Inc
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Disc Medicine, Inc. – IRON
From Pomerantz LLP
Via GlobeNewswire
News headline image
Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation – IRON
From The Rosen Law Firm, P.A.
Via Business Wire
News headline image
IRON Investors Have Opportunity to Join Disc Medicine, Inc. Fraud Investigation with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
IRON Investors Have Opportunity to Join Disc Medicine, Inc. Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Disc Medicine, Inc. - IRON
From Pomerantz LLP
Via GlobeNewswire
News headline image
Disc Medicine Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
From Disc Medicine Inc
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Disc Medicine, Inc.- IRON
From Pomerantz LLP
Via GlobeNewswire
News headline image
Disc Medicine to Participate in Upcoming Investor Conferences
From Disc Medicine Inc
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Disc Medicine, Inc.- IRON
From Pomerantz LLP
Via GlobeNewswire
News headline image
Disc Medicine Receives Complete Response Letter from FDA for Bitopertin for the Treatment of EPP
From Disc Medicine Inc
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Disc Medicine, Inc.- IRON
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Disc Medicine, Inc. – IRON
From Pomerantz LLP
Via GlobeNewswire
News headline image
Disc Medicine Appoints Lisa Amaya Price, MBA as Chief Human Resources Officer
From Disc Medicine Inc
Via GlobeNewswire
News headline image
Disc Medicine Highlights Recent Achievements and Key Business Objectives and Milestones for 2026
From Disc Medicine Inc
Via GlobeNewswire
News headline image
Disc Medicine to Present at the 44th Annual J.P. Morgan Healthcare Conference
From Disc Medicine Inc
Via GlobeNewswire
News headline image
Disc Medicine Presents Positive Initial Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 67th American Society of Hematology (ASH) Annual Meeting
From Disc Medicine Inc
Via GlobeNewswire
News headline image
Disc Medicine Reports Third Quarter 2025 Financial Results and Provides Business Update
From Disc Medicine Inc
Via GlobeNewswire
News headline image
Disc Medicine Announces Presentation of Initial Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 67th American Society of Hematology (ASH) Annual Meeting
From Disc Medicine Inc
Via GlobeNewswire
News headline image
Disc Medicine to Participate in Upcoming Investor Conferences
From Disc Medicine Inc
Via GlobeNewswire
News headline image
Disc Medicine Announces Pricing of $250 Million Upsized Public Offering of Common Stock and Pre-Funded Warrants
From Disc Medicine Inc
Via GlobeNewswire
News headline image
Disc Medicine Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
From Disc Medicine Inc
Via GlobeNewswire
News headline image
Disc Medicine Provides Update on Hematology Portfolio and Outlines Near-Term Business Objectives and Anticipated Milestones
From Disc Medicine Inc
Via GlobeNewswire
News headline image
Disc Medicine to Present Data from Phase 1b Trial of DISC-0974 in Patients with Chronic Kidney Disease (CKD) and Anemia at 2025 American Society of Nephrology (ASN) Kidney Week
From Disc Medicine Inc
Via GlobeNewswire
News headline image
Disc Medicine Announces Receipt of FDA Commissioner’s National Priority Voucher (CNPV) for Bitopertin in Erythropoietic Protoporphyria (EPP)
From Disc Medicine Inc
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.